

CURRICULUM VITAE WITH TRACK RECORD

PERSONAL INFORMATION

Killingberg, Kristin Toftaker

Date of birth: 30.11.1968

Sex: Female

Nationality: Norwegian

<mailto:Kristin.t.killingberg@ntnu.no>

Phone number +47 47386257

ORCID <https://orcid.org/0000-0002-1354-9823>

URL

https://scholar.google.com/citations?view_op=list_works&hl=no&user=FbOW2HYAAAAJ

EDUCATION

- 2023 PhD: Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer. Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and technology NTNU, Norway
- 2017 Specialist in Oncology, Medical Oncology and Radiotherapy
- 2008 Specialist in Family Medicine
- 1996 MD:
Faculty of Medicine and Health Sciences, Norwegian University of Science and technology NTNU, Norway

CURRENT AND PREVIOUS POSITIONS

Current Position

- 2023 - Post-doc
Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and technology NTNU, Norway
- 2017 - Senior Consultant in Medical Oncology and Radiotherapy,
The Cancer Clinic, St.Olavs Hospital, Trondheim, with main responsibility for treatment of patient with lung cancer.

Previous positions held

- 2016-2017 Resident, Clinic of Internal Medicine, department of haematology, St. Olavs Hospital, Trondheim
- 2013-2015 Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim
- 2012-2013 General practitioner (GP), Oppdal kommune, Sør-Trøndelag
- 2011-2012 Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim
- 2008-2011 General practitioner (GP), Oppdal kommune, Sør-Trøndelag
- 2006-2008 Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim, Norway
- 2002-2006 General practitioner (GP), Rennebu kommune, Sør-Trøndelag

2000-2002 General practitioner (GP), Oppdal kommune, Sør-Trøndelag
1997 Internship in Internal Medicine and Surgery, Hospital of Molde,
1998 Internship in General Practice, Aukra kommune, Møre and Romsdal

TEACHING ACTIVITIES

2000-2012 Supervisor for medical students in family medicine
2006 - dd Lectures in oncology at several Departments at St. Olavs Hospital, especially the Cancer Clinic, for physicians and specialist-candidates in Oncology.
2014- dd Instructor at course in communication skills for medical students
"breaking bad news", Norwegian University of science and technology
2010 - dd Lectures in cancer therapy for Oncology nurses in Trondheim (NTNU)
2010-dd. Lectures in cancer therapy for physiotherapists

PROJECT MANAGEMENT EXPERIENCE

Involved in the daily running of all clinical trials on lung cancer at the Department Oncology, St. Olavs hospital.

2023- A randomized phase II, open-label, multicenter study investigating efficacy and safety² of anti-PD1/PD-L1 treatment +/- UVI vaccination as first line treatment in patients with inoperable advanced of metastatic non-small cell
2023 - Combinatory immunotherapy-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer, local investigator, sponsored by Oslo University Hospital
2019- A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer (ACHILES), funded by the Liaison Committee for Education, Research and Innovation in Central Norway, sponsored by the Norwegian University of Science and Technology (NTNU), Norway

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

2021-2024 Main supervisor of one PhD student
2023- co-supervisor of 2 PhD students

MAJOR COLLABORATIONS

Project manager, Bjørn Henning Grønberg (BHG), professor at Department of Clinical and Molecular Medicine, NTNU, and Consultant in Oncology at Department of Oncology, St. Olav's hospital. He is leader of the Cancer and Palliative Care Research Group (CPRG) at NTNU.

Key members of our laboratory analyses group include:

- Hong Yan Dai (HYD), researcher/molecular biologist, pathology dept., St. Olavs hospital
- Vibeke Grotnes Dale (VGD), consultant in pathology, SOH, specializes in SCLC

Key members of the clinical research group include:

- Tarje Onsøien Halvorsen (TOH), post-doctor, consultant at oncology dept. SOH
- Arne Solberg (AS), researcher, oncologist
- Marie Søfteland Sandvei (MSS), researcher, resident at oncology dept. SOH
- Nina Levin (NL) Msc, Medical physicist, Oncology department, st Olav, PhD candidate NTNU

Track record, publication list

28 publications last 10 years

<input type="checkbox"/>	TITTEL	SITERT AV	ÅR
<input type="checkbox"/>	<p>Changes in use of radiotherapy for lung cancer—A Norwegian population-based study from 2000 until 2020</p> <p>G Graabak, TO Halvorsen, BH Grønberg, KT Killingberg Lung Cancer, 108720</p>		2025
<input type="checkbox"/>	<p>Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer</p> <p>F Cortes-Figueiredo, HM Zachariassen, K Killingberg, T Halvorsen, ... Journal of Thoracic Oncology 20 (8), S34-S35</p>		2025
<input type="checkbox"/>	<p>Subtyping Small Cell Lung Cancer Reveals Inflammatory Subtypes with Improved Radiosensitivity and Chemoradiotherapy Outcomes</p> <p>R Oliveira, BH Grønberg, T Halvorsen, K Killingberg, P Sætrum Journal of Thoracic Oncology 20 (8), S39</p>		2025
<input type="checkbox"/>	<p>High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open ...</p> <p>BH Grønberg, KT Killingberg, MM Bjaanæs, OT Brustugun, T Madebo, ... Journal of Thoracic Oncology 20 (8), 1108-1119</p>	1	2025
<input type="checkbox"/>	<p>Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC ...</p> <p>M Grønberg, M Aanerud, TO Halvorsen, KT Killingberg, BH Grønberg Lung Cancer, 108678</p>	1	2025
<input type="checkbox"/>	<p>Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).</p> <p>BH Grønberg, M Aanerud, DW Dumoulin, J Nyman, T Schytte, ... Journal of Clinical Oncology 43 (17_suppl), LBA8005-LBA8005</p>	2	2025
<input type="checkbox"/>	<p>Time until treatment, treatment time and outcomes of chemoradiotherapy (CRT) in limited stage (LS) small cell lung cancer (SCLC): 335P</p> <p>M Grønberg, TO Halvorsen, M Aanerud, KT Killingberg, BH Grønberg Journal of Thoracic Oncology 20 (3), S202-S203</p>		2025
<input type="checkbox"/>	<p>335P: Time until treatment, treatment time and outcomes of chemoradiotherapy (CRT) in limited stage (LS) small cell lung cancer (SCLC)</p> <p>M Grønberg, TO Halvorsen, M Aanerud, KT Killingberg, BH Grønberg Journal of Thoracic Oncology 20 (3), S202-S203</p>		2025
<input type="checkbox"/>	<p>High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open ...</p> <p>BH Grønberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, OT Brustugun, ... Journal of Thoracic Oncology</p>	6	2025

<input type="checkbox"/>	Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC E Taranova, M Aanerud, TO Halvorsen, KT Killingberg, M Slaaen, ... JTO Clinical and Research Reports 6 (1), 100764	3	2025
<input type="checkbox"/>	Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy: P1. 13A. 06 M Grønberg, TO Halvorsen, BH Grønberg, KT Killingberg, M Aanerud Journal of Thoracic Oncology 19 (10), S207-S209		2024
<input type="checkbox"/>	Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy M Gronberg, TO Halvorsen, BH Gronberg, KT Killingberg, M Aanerud JOURNAL OF THORACIC ONCOLOGY 19 (10), S207-S209		2024
<input type="checkbox"/>	P1. 13A. 06 Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy M Grønberg, TO Halvorsen, BH Grønberg, KT Killingberg, M Aanerud Journal of Thoracic Oncology 19 (10), S207-S209		2024
<input type="checkbox"/>	Evaluation of radiation therapy treatment plans in a randomized Phase 2 trial comparing 2 schedules of twice-daily thoracic radiation therapy in limited stage small cell lung ... N Levin, KT Killingberg, TO Halvorsen, S Danielsen, BH Grønberg International Journal of Radiation Oncology* Biology* Physics 120 (2), 332-342	7	2024
<input type="checkbox"/>	Effect of FDG PET-CT for Staging and Radiotherapy Planning—A Comparison of Cohorts From Two Randomized Trials of Thoracic Radiotherapy in Limited-Stage SCLC G Graabak, BH Grønberg, KT Killingberg, TO Halvorsen JTO Clinical and Research Reports 5 (9), 100688	2	2024
<input type="checkbox"/>	Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of ... E Taranova, BHH Gronberg, TO Halvorsen, KT Killingberg, M Slaaen, ... Journal of Clinical Oncology 41 (16_suppl), 8519-8519	1	2023
<input type="checkbox"/>	Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung ... BHH Gronberg, KT Killingberg, Ø Fløtten, MM Bjaanaes, T Madebo, ... Journal of Clinical Oncology 41 (16_suppl), 8512-8512	6	2023
<input type="checkbox"/>	Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited-stage SCLC KT Killingberg, BH Grønberg, M Slaaen, Ø Kirkevold, TO Halvorsen Journal of Thoracic Oncology 18 (6), 803-812	11	2023
<input type="checkbox"/>	Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer KT Killingberg NTNU		2023

<input type="checkbox"/>	Associations between measured and patient-reported physical function and survival in advanced NSCLC K Stokke, TO Halvorsen, BH Grønberg, I Saltvedt, M Slaaen, Ø Kirkevold, ... Healthcare 10 (5), 922	4	2022
<input type="checkbox"/>	OC-0440 Comparing target volumes in a randomized trial of high-dose radiotherapy in small cell lung cancer N Levin, S Danielsen, TO Halvorsen, KT Killingberg, KR Redalen, ... Radiotherapy and Oncology 170, S384-S385		2022
<input type="checkbox"/>	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small ... KT Killingberg, TO Halvorsen, Ø Fløtten, OT Brustugun, SW Langer, ... Lung Cancer 166, 49-57	8	2022
<input type="checkbox"/>	Prognostic value of post first-line chemotherapy Glasgow prognostic score in advanced non-small cell lung cancer K Stokke, MS Sandvei, BH Grønberg, M Slaaen, KT Killingberg, ... Clinical Medicine Insights: Oncology 16, 11795549221086578	5	2022
<input type="checkbox"/>	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331	145	2021
<input type="checkbox"/>	Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC TO Halvorsen, K Stokke, KT Killingberg, SX Raj, S Sørhaug, ... Acta Oncologica 59 (9), 1051-1057	6	2020
<input type="checkbox"/>	17830 Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small ... BH Grønberg, KT Killingberg, K Stokke, TO Halvorsen Annals of Oncology 31, S1032		2020
<input type="checkbox"/>	Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). BH Grønberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, T Madebo, ... Journal of Clinical Oncology 38 (15_suppl), 9007-9007	10	2020
<input type="checkbox"/>	P1. 01-09 Randomized Trial Comparing Maintenance Pemetrexed with Observation Followed by Pemetrexed at Progression in Advanced NSCLC K Stokke, TO Halvorsen, Ø Fløtten, S Sørhaug, T Madebo, S Raj, ... Journal of Thoracic Oncology 14 (10), S357-S358		2019

3.Conference proceedings

2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bjørn H Grønberg Marianne Aanerud, Daphne W. Dumoulin, Jan Nyman, Tine Schytte, Maria Moksnes Bjaanæs, Kirill Neumann, Georgios Tsakonas, Elisabeth Anna Kastelij, Nina Helbekkmo, Seppo W. Langer, Sacha Rothschild, Christina Appenzeller, Jos Stigt, Tine McCulloch, Hanne Sorger, Marie Søfteland Sandvei, Kristin Toftaker Killingberg, Trude Camilla Frøseth, Tarje Onsøien Halvorsen
Journal of Clinical Oncology 2025 43:17_suppl, LBA8005-LBA8005
DOI:[10.1200/JCO.2025.43.17_suppl.LBA8005](https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA8005)

IASLC 2025 Hot Topic in Basic & Translational Science: Small Cell Lung Cancer. 2-4 April 2025 • New York, USA

Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer
F Cortes-Figueiredo, HM Zachariassen, K Killingberg, T Halvorsen, ...
Journal of Thoracic Oncology 20 (8), S34-S35

IASLC 2025 Hot Topic in Basic & Translational Science: Small Cell Lung Cancer. 2-4 April 2025 • New York, USA

Subtyping Small Cell Lung Cancer Reveals Inflammatory Subtypes with Improved Radiosensitivity and Chemoradiotherapy Outcomes
R Oliveira, BH Grønberg, T Halvorsen, K Killingberg, P Sætrum
Journal of Thoracic Oncology 20 (8), S39

2024 World conference on Lung Cancer

M. Grønberg, T.O. Halvorsen, B.H. Grønberg, K.T. Killingberg, M. Aanerud,
P1.13A.06 Outcomes in LS SCLC Patients with Severe Acute Esophagitis During
Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy,
Journal of Thoracic Oncology, Volume 19, Issue 10, Supplement, 2024, Pages S207-S209,
ISSN 1556-0864, <https://doi.org/10.1016/j.jtho.2024.09.375>.

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).

Evgenia Taranova, Bjorn H. Henning Gronberg, Tarje Onsøien Halvorsen, Kristin Toftaker Killingberg, Marit Slaaen, Marianne Aanerud
Journal of Clinical Oncology 2023 41:16_suppl, 8519-8519

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).

Bjorn H. Henning Gronberg, Kristin Toftaker Killingberg, Øystein Fløtten, Maria Moksnes Bjaanæs, Tesfaye Madebo, Tine Schytte, Seppo Wang Langer, Signe Leonora Risumlund, Nina Helbekkmo, Kirill Neumann, Odd Terje Brustugun, Øyvind Yksnøy, Georgios Tsakonas, Jens Engleson, Sverre Fluge, Thor Naustdal, Liv Ellen Giske, Jan Nyman, Tarje Onsøien Halvorsen
Journal of Clinical Oncology 2023 41:16_suppl, 8512-8512

BiGART, Aarhus, Danmark, 20. juni 2023, Acta Oncologica

Dose-response of acute esophagitis for limited stage small cell lung cancer - Data from a randomized phase II trial

Nina Levin, Signe Danielsen, Tarje Onsøien Halvorsen, Kristin Toftaker Killingberg, Kathrine Røe Redalen, Bjørn Henning Grønberg

2019 World Conference on Lung Cancer

Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer.

Stokke K, Sandvei MS, Grønberg BH, Slaaen M, Killingberg KT, Halvorsen TO. Clin Med Insights Oncol. 2022 Mar 22; 16:11795549221086578. doi: 10.1177/11795549221086578. eCollection 2022. PMID: 35342321

ESMO Virtual Congress 2020

1783O Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small ...

BH Gronberg, KT Killingberg, K Stokke, TO Halvorsen
Annals of Oncology 31, S1032

2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small cell lung cancer (LD SCLC)

Bjorn Henning Gronberg, Kristin Toftaker Killingberg, Øystein Fløtten, Maria Moksnes Bjaanæs, Tesfaye Madebo, Seppo Langer, Tine Schytte, Odd Terje Brustugun, Jan Nyman, Kristin Stokke, and Tarje Onsøien Halvorsen
Journal of Clinical Oncology 2020 38:15_suppl, 9007-9007

European Society for Therapeutic Radiology and Oncology (ESTRO) Congress 2022

Target volumes in a randomized trial comparing high-dose versus standard-dose twice daily radiotherapy in limited stage small cell lung cancer.

Nina Levin, Signe Danielsen, Tarje Onsøien Halvorsen, Kristin Toftaker Killingberg, Kathrine Røe Redalen, Bjørn Henning Grønberg.

1. Prizes/ Awards/ Academy memberships

Publikasjonsprisen 2021 Institutt for klinisk og molekylær medisin, NTNU

Bjørn Henning Grønberg, Kristin T Killingberg og Tarje Halvorsen

For the publication In Lancet Oncology: High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

Årets publikasjon 2021 St Olavs hospital

“High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomized phase 2 trial” - The Lancet Oncology 2021; 22(3): 321-331

Kreftklinikken v. Bjørn Henning Grønberg, Kristin T Killingberg og Tarje Halvorsen